As an m6A methylation reader, IGF2BP2 triggers endothelial cell activation, facilitating angiogenesis and metastatic spread of LUAD cells (82), and IGF2BP2 is considered a potential immune biomarker in head and neck squamous cell carcinoma (83). Here, IGF2BP2 is linked to head and neck squamous cell carcinoma.